Health Condition 1: R634- Abnormal weight loss Health Condition 2: R630- Anorexia
Conditions
Interventions
Intervention1: Olanzapine: 5mg per day HS FOR 28 days
Control Intervention1: Mirtazapine: 15mg per day HS for 28 days
Sponsors
Arun Kumar Garg
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age 18 years and above. 2. Registered in the palliative care centre. 3. Suffering from histologically diagnosed advanced cancer (Cancer with metastasis). 4. Patients with a weight loss of more than 5 percent of body weight over the past 6 months or loss of 2-5 percent of body weight over the past 6 months plus Body Mass Index (BMI) of less than 20. 5. Loss of appetite score (SNAQ score less than 14). 6. Patient giving written informed consent for this Study.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating female. 2. Known history of hypersensitivity to study drugs. 3. Severe renal impairment (creatinine more than 2). 4. Severe liver impairment (Child Pugh score more than 10). 5. Significant disorder of bone marrow. 6. Severe cardiac impairment. 7. Patient taking antipsychotic, sedative psychotropic drug, atropine, and its substitute. 8. Non cooperative patient.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in body weight of the patients from baseline to the 2nd and 4th weeks after starting treatment.Timepoint: At the 2nd and 4th weeks after starting treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in HADS (Hospital Anxiety and Depression Scale) scoresTimepoint: At the 2nd and 4th weeks after starting treatment;Change in LSEQ (Leeds Sleep Evaluation Questionnaire) scoresTimepoint: At the 2nd and 4th weeks after starting treatment;Change in VAS (Visual Analogue Scale) scores for nausea and vomitingTimepoint: At the 2nd and 4th weeks after starting treatment | — |
Countries
India
Contacts
Public ContactDr Deepak Kumar Garg
JLN Medical College, Ajmer
Outcome results
None listed